open access

Vol 21, No 3 (2014)
Review paper
Published online: 2014-06-09
Get Citation

Long time clinical outcomes of limus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary artery intervention: A meta-analysis of randomized controlled clinical trials

Lei Gao, Xin Hu, Yuntian Hou, Qiao Xue
DOI: 10.5603/CJ.a2014.0004
·
Cardiol J 2014;21(3):211-219.

open access

Vol 21, No 3 (2014)
Review articles
Published online: 2014-06-09

Abstract

Background: The meta-analysis was aimed to compare the long time (> 2 year) clinical outcomes of limus-based stents (LBS) and paclitaxel-eluting stents (PES). LBS and PES are two kinds of most common coronary artery stents in clinics.

Methods: Electronic data bases of PubMed, Cochrane, and EMBASE were searched. We included randomized controlled clinical trials (RCT) comparing LBS and PES with long time clinical outcomes. Methodological quality of eligible trials was assessed using “risk of bias” tool. The efficacy endpoints included target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST), and the safety endpoints included all cause death, cardiac death, and myocardial infarction (MI). Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated for each endpoint.

Results: A total of 23 RCTs and 19,319 participants were included and analyzed in this meta-analysis. All trials were of an acceptable quality. At 2 years, LBS showed reduced risk of revascularization and ST (TLR: OR = 0.59, 95% CI 0.44–0.78; TVR: OR = 0.63, 95% CI 0.55–0.71; ST: OR = 0.55, 95% CI 0.41–0.73) and a lower rate of MI (OR = 0.67, 95% CI 0.57–0.79). Subgroup analysis showed that both everolimus-eluting stents and sirolimus-eluting stents had better clinical outcomes compared with PES. The comparisons of 3, 4 and 5 year follow-up results revealed that the clinical outcomes of PES were non-inferior to those of LBS but LBS was associated with reduced risk of MI and ST at 3 years.

Conclusions: LBS is associated with better clinical outcomes at 2 years. Both LBS and PES showed similar efficacy and safety at long time period.

Abstract

Background: The meta-analysis was aimed to compare the long time (> 2 year) clinical outcomes of limus-based stents (LBS) and paclitaxel-eluting stents (PES). LBS and PES are two kinds of most common coronary artery stents in clinics.

Methods: Electronic data bases of PubMed, Cochrane, and EMBASE were searched. We included randomized controlled clinical trials (RCT) comparing LBS and PES with long time clinical outcomes. Methodological quality of eligible trials was assessed using “risk of bias” tool. The efficacy endpoints included target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST), and the safety endpoints included all cause death, cardiac death, and myocardial infarction (MI). Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated for each endpoint.

Results: A total of 23 RCTs and 19,319 participants were included and analyzed in this meta-analysis. All trials were of an acceptable quality. At 2 years, LBS showed reduced risk of revascularization and ST (TLR: OR = 0.59, 95% CI 0.44–0.78; TVR: OR = 0.63, 95% CI 0.55–0.71; ST: OR = 0.55, 95% CI 0.41–0.73) and a lower rate of MI (OR = 0.67, 95% CI 0.57–0.79). Subgroup analysis showed that both everolimus-eluting stents and sirolimus-eluting stents had better clinical outcomes compared with PES. The comparisons of 3, 4 and 5 year follow-up results revealed that the clinical outcomes of PES were non-inferior to those of LBS but LBS was associated with reduced risk of MI and ST at 3 years.

Conclusions: LBS is associated with better clinical outcomes at 2 years. Both LBS and PES showed similar efficacy and safety at long time period.

Get Citation

Keywords

target vessel revascularization, limus-based stents, paclitaxel-eluting stents, percutaneous coronary intervention

About this article
Title

Long time clinical outcomes of limus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary artery intervention: A meta-analysis of randomized controlled clinical trials

Journal

Cardiology Journal

Issue

Vol 21, No 3 (2014)

Article type

Review paper

Pages

211-219

Published online

2014-06-09

DOI

10.5603/CJ.a2014.0004

Bibliographic record

Cardiol J 2014;21(3):211-219.

Keywords

target vessel revascularization
limus-based stents
paclitaxel-eluting stents
percutaneous coronary intervention

Authors

Lei Gao
Xin Hu
Yuntian Hou
Qiao Xue

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl